COVID is BACK! 15% spike in cases in US, is ‘Cicada’ variant next wave?

In a 𝓈𝒽𝓸𝒸𝓀𝒾𝓃𝑔 resurgence, COVID-19 cases have spiked 15% across the United States, with the highly mutated Cicada variant, BA.3.2, emerging as a potential next wave threat. Health officials report this strain is rapidly spreading, now accounting for over 20% of infections based on recent wastewater data, raising urgent alarms for public health.

The Cicada variant first gained notice earlier this year, detected in 23 countries and dominating up to 30% of cases in parts of Eastern Europe. In the US, it started as a minor player, less than 4% of cases in mid-March, but has surged to alarming levels by early April. This rapid ascent underscores the virus’s evolving nature, evading prior defenses.

Experts warn that Cicada, nicknamed for its elusive emergence like the insect, originated from a traveler in June 2025. Dr. Robert H. Hopkins Jr. notes it remained under the radar until recent outbreaks. Now, it’s appearing in wastewater samples from 132 sites across 25 states, signaling widespread circulation that demands immediate vigilance.

Symptoms mirror typical COVID strains, including fever, fatigue, cough, and loss of taste or smell, but the variant’s mutations could make it more transmissible. As cases climb, the Centers for Disease Control and Prevention tracks its spread in states like California, New York, and Texas, urging heightened monitoring to prevent overwhelming healthcare systems.

This development comes amid growing concerns from medical experts like Dr. Peter McCullough, who highlights the broader implications of 𝓿𝒾𝓇𝒶𝓁 variants and vaccine responses. In his testimony, McCullough emphasized the need for robust public health strategies, pointing to the virus’s potential for severe outcomes in vulnerable populations.

The CDC’s latest data from February shows Cicada in diverse regions, from Hawaii to Wyoming, painting a picture of nationwide vulnerability. While overall COVID activity had waned since winter, this variant’s rise disrupts that calm, forcing officials to reassess containment measures and booster efficacy.

Public health experts are calling for swift action, including mask mandates in high-risk areas and expanded testing. The variant’s underground spread, as described by Hopkins, means it could have been circulating longer than realized, amplifying the urgency for community-wide precautions.

In light of this spike, the World Health Organization is monitoring global patterns, with Cicada already a concern in Europe. US residents are advised to stay informed through reliable sources, as the variant’s growth rate could lead to localized outbreaks if not addressed promptly.

Dr. McCullough’s insights from his extensive experience add layers to the crisis, stressing that variants like Cicada highlight the limitations of current defenses. His analysis of vaccine-related data underscores the importance of adaptive strategies, though the focus remains on curbing this new threat.

As the nation grapples with this escalation, economic impacts loom large, with potential disruptions to schools, businesses, and travel. The 15% case increase reported in preliminary figures signals a pivotal moment, where decisive interventions could avert a full-scale wave.

Health authorities are racing to update guidelines, emphasizing that early detection is key. Wastewater surveillance, led by Stanford’s tool, has proven invaluable in spotting rises before traditional testing, offering a critical edge in this fast-evolving scenario.

The Cicada variant’s mutations raise questions about vaccine effectiveness, with experts like McCullough pointing to ongoing research needs. His testimony before Congress detailed thousands of cases he’s examined, underscoring the virus’s persistent dangers and the call for comprehensive responses.

In states like Florida and Texas, where cases are climbing, local officials are activating emergency protocols. This variant’s spread from just 25 states could expand, making nationwide preparedness essential to mitigate risks.

Public awareness campaigns are ramping up, urging symptoms monitoring and isolation. The urgency is palpable, as every day counts in containing Cicada’s momentum and preventing it from becoming the dominant strain.

Dr. McCullough’s peer-reviewed work, with over 700 citations, reinforces the need for evidence-based action. His warnings about 𝓿𝒾𝓇𝒶𝓁 proteins and their impacts highlight why this variant demands immediate scrutiny.

As COVID fatigue sets in for many, this resurgence serves as a stark reminder of the pandemic’s unpredictability. With summer approaching, outdoor activities and gatherings could fuel transmission, necessitating renewed caution.

The CDC has not yet classified Cicada in its monthly surveillance, but the evidence is mounting. Health experts are advocating for booster shots and treatments, drawing from lessons learned in prior waves.

In interviews, officials stress that while the variant shares symptoms with earlier strains, its rapid spread warrants extra vigilance. This is not a repeat of past peaks, but a new chapter in the ongoing battle.

Dr. McCullough’s testimony brings a human element, recounting cases of severe outcomes and the importance of do-no-harm principles in public health. His call for stopping unsubstantiated claims ensures that responses are grounded in science.

With global eyes on the US, the 15% spike could influence international travel policies, potentially leading to restrictions. This variant’s emergence in a post-peak period adds to the 𝒹𝓇𝒶𝓂𝒶, as the world watches for ripple effects.

Communities are mobilizing, with volunteer testing sites and education drives gaining traction. The fight against Cicada is a collective one, requiring unity to protect the most at-risk groups.

As data pours in, the narrative is clear: COVID is not in the rearview mirror. The Cicada variant’s rise is a call to action, demanding that we adapt and respond with the same urgency that defined the pandemic’s early days.

Health organizations are prioritizing research into Cicada’s specifics, including its transmission rates and potential for severe illness. This focused effort could yield breakthroughs, but time is of the essence.

Dr. McCullough’s extensive publications provide a foundation for understanding 𝓿𝒾𝓇𝒶𝓁 threats, emphasizing that complacency is not an option. His insights into myocarditis and other complications serve as a cautionary tale.

In closing, the 15% spike and Cicada’s ascent mark a critical juncture. With proactive measures, we can blunt this wave, but the window for action is narrowing, making every decision count in this high-stakes health crisis.